Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05690464 · ClinicalTrials.gov registry record · NA

Effect of Magnesium Supplementation on Elevated Systolic Blood Pressure

A NA study of Blood Pressure, sponsored by Brigham and Women's Hospital.

Active
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT05690464 is a NA study of Blood Pressure that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 120 participants, below the 286-participant average among 101 other Blood Pressure trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05690464, a NA study of Blood Pressure, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess whether 480 mg/day magnesium glycinate supplementation for 12 weeks lowers blood pressure.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT magnesium glycinate supplement
  • DIETARY_SUPPLEMENT placebo

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2023-01-17
Est. Completion 2026-05
Phase NA

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT05690464

The ClinicalTrials.gov registry entry for NCT05690464 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 286-participant average among 101 other Blood Pressure trials with a reported enrollment target (58% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Blood Pressure appearing as the primary indexed condition, and to 2 interventions - of which magnesium glycinate supplement is the first listed.

NCT05690464 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05690464 about?

NCT05690464 is a clinical study titled "Effect of Magnesium Supplementation on Elevated Systolic Blood Pressure". The purpose of this study is to assess whether 480 mg/day magnesium glycinate supplementation for 12 weeks lowers blood pressure.

What is the current status of trial NCT05690464?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2023-01-17. Estimated completion is 2026-05.

What conditions does trial NCT05690464 study?

This clinical trial studies the following conditions: Blood Pressure.

What interventions are being tested in trial NCT05690464?

The interventions under investigation include: magnesium glycinate supplement (DIETARY_SUPPLEMENT), placebo (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05690464?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05690464 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Blood Pressure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.